Avoiding Neuromuscular Blockers to Reduce Complications

• Status: Suspended
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Treatments: Analgesics, Opioid; Anesthetics; Dexmedetomidine; Ketamine; Neuromuscular Blocking Agents; Propofol; Rocuronium

Criteria

Inclusion Criteria:

• At least 18 years of age

• Undergoing non-cardiac surgery under general anesthesia with an endotracheal tube

• those at higher risk of developing postoperative pulmonary complications (internally validated risk prediction score of >=20)

Exclusion Criteria:

• Emergency surgery

• Ambulatory (outpatient) surgery

• Scheduled for elective postoperative ventilation

• Planned return to operating room within 7 days of index procedure

• Exposure to general anesthesia within 7 days prior to planned procedure

• Requirement mechanical ventilation at baseline (not including stable use of CPAP/BiPAP)

• Pregnant patients: as detected by patient self-reporting or diagnosed by preoperative pregnancy testing according to institutional policies at BIDMC and MGH

• Allergy to either non-depolarizing muscle relaxants or sugammadex

• Clinician refusal

• Prisoner